Effective protection for >5 years with bay 94-9027 prophylaxis: interim results from the protect VIII extension trial

被引：0
|
作者：
Thomson, G. [1 ]
Holme, P. A. [2 ,3 ]
Wang, M. [4 ]
Enriquez, M. Maas [5 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haemostasis & Thrombosis, London, England
[2] Oslo Univ Hosp, Dept Haematol, Oslo, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Bayer, Whippany, NJ USA
[5] Bayer AG, Wuppertal, Germany
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P170
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [1] Safety of long-term prophylaxis with BAY 94-9027: Interim results of >5 years of treatment in the PROTECT VIII extension trial
    Reding, Mark T.
    Ng, Hen Joo
    Tseneklidou-Stoefer, Despina
    Linardi, Camila
    Lalezari, Shadan
    [J]. HAEMOPHILIA, 2018, 24 : 17 - 18
  • [2] BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
    Lalezari, Shadan
    Reding, Mark T.
    Pabinger, Ingrid
    Holme, Pal Andre
    Negrier, Claude
    Chalasani, Pavani
    Shin, Ho-Jin
    Wang, Maria
    Tseneklidou-Stoeter, Despina
    Maas Enriquez, Monika
    [J]. HAEMOPHILIA, 2019, 25 (06) : 1011 - 1019
  • [3] EFFECTIVE PROPHYLAXIS WITH BAY 94-9027 IN ADOLESCENTS WITH HEMOPHILIA A: RESULTS FROM THE PROTECT VIII MAIN STUDY AND ONGOING EXTENSION
    Kerlin, Bryce
    Ducore, Jonathan
    Ahuja, Sanjay
    Afonja, Olubunmi
    Saxena, Kapil
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65
  • [4] CONFIRMED SAFETY PROFILE OF BAY 94-9027 PROPHYLAXIS FOR ≥5 YEARS: OUTCOMES FROM THE PROTECT VIII AND PROTECT VIII KIDS EXTENSION STUDIES
    Mancuso, M. E.
    Holme, P. A.
    Kenet, G.
    Simpson, M.
    Di Minno, M. N. D.
    Baumann, A.
    Enriquez, Maas M.
    Reding, M. T.
    [J]. HAEMATOLOGICA, 2021, 106 (09) : 7 - 8
  • [5] BAY 94-9027 provides effective long-term prophylaxis in pediatric patients: Interim results of the PROTECT VIII Kids extension study
    Kenet, Gili
    Biss, Tina
    Steele, MacGregor
    Linardi, Camila
    Tseneklidou-Stoeter, Despina
    Saxena, Kapil
    [J]. HAEMOPHILIA, 2018, 24 : 15 - 15
  • [6] EFFICACY AND SAFETY OF BAY 94-9027 IS SUSTAINED FOR 5 YEARS: OUTCOMES IN PATIENTS FROM THE PROTECT VIII AND PROTECT VIII KIDS EXTENSION STUDIES
    Santagostino, E.
    Di Minno, M. N. D.
    Lalezari, S.
    Kenet, G.
    Enriquez, M. Maas
    Wang, M.
    Reding, M.
    [J]. HAEMOPHILIA, 2020, 26 : 73 - 73
  • [7] BAY 94-9027 EFFICACY/SAFETY SUSTAINED FOR 5 YEARS: DATA FROM 33 PATIENTS (PROTECT VIII EXTENSION)
    Reding, Mark
    Poulsen, Lone
    Liu, Tian
    Holme, Pal Andre
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66
  • [8] BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study
    Ahuja, Sanjay
    Fischer, Kathelijn
    Biss, Tina
    Enriquez, Monika Maas
    Mancuso, Maria-Elisa
    Steele, MacGregor
    Wang, Maria
    Kenet, Gili
    [J]. BLOOD, 2020, 136
  • [9] Protect VIII: Effective Protection With BAY 94-9027 Prophylaxis Given Twice Weekly, Every 5 Days, Or Every 7 Days
    Negrier, C.
    Chambost, H.
    Poulsen, L. H.
    Enriquez, M. Maas
    Lalezari, S.
    Pabinger, I.
    Wang, M.
    [J]. HAEMOPHILIA, 2017, 23 : 100 - 101
  • [10] COMPARISON OF BLEEDING RATES BEFORE AND DURING BAY 94-9027 PROPHYLAXIS: DATA FROM THE PROTECT VIII STUDY AND EXTENSION
    Kerlin, Bryce A.
    Simpson, Mindy L.
    Reding, Mark T.
    Linardi, Camila
    Schwartz, Lawrence
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E32 - E32
12345